177 related articles for article (PubMed ID: 30729531)
1. Factors affecting lymphocyte collection efficiency for the manufacture of chimeric antigen receptor T cells in adults with B-cell malignancies.
Tuazon SA; Li A; Gooley T; Eunson TW; Maloney DG; Turtle CJ; Linenberger ML; Connelly-Smith LS
Transfusion; 2019 May; 59(5):1773-1780. PubMed ID: 30729531
[TBL] [Abstract][Full Text] [Related]
2. Lymphocyte apheresis for chimeric antigen receptor T-cell manufacturing in children and young adults with leukemia and neuroblastoma.
Ceppi F; Rivers J; Annesley C; Pinto N; Park JR; Lindgren C; Mgebroff S; Linn N; Delaney M; Gardner RA
Transfusion; 2018 Jun; 58(6):1414-1420. PubMed ID: 29536556
[TBL] [Abstract][Full Text] [Related]
3. Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients with Relapsed/Refractory NHL or ALL.
Korell F; Laier S; Sauer S; Veelken K; Hennemann H; Schubert ML; Sauer T; Pavel P; Mueller-Tidow C; Dreger P; Schmitt M; Schmitt A
Cells; 2020 May; 9(5):. PubMed ID: 32429189
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of cell collection efficiency in non-mobilized adult donors for autologous chimeric antigen receptor T-cell manufacturing.
Piñeyroa JA; Cid J; Vlagea A; Carbassé G; Henao P; Bailo N; Ortiz-Maldonado V; Martínez-Cibrian N; Español M; Delgado J; Urbano-Ispizua Á; Lozano M
Vox Sang; 2023 Mar; 118(3):217-222. PubMed ID: 36516201
[TBL] [Abstract][Full Text] [Related]
5. A Clinically Applicable Prediction Model to Improve T Cell Collection in Chimeric Antigen Receptor T Cell Therapy.
Jo T; Yoshihara S; Hada A; Arai Y; Kitawaki T; Ikemoto J; Onomoto H; Sugiyama H; Yoshihara K; Obi N; Matsui K; Niwa N; Nakagawa Y; Kanda J; Kondo T; Saida S; Kato I; Hiramatsu H; Adachi S; Takita J; Takaori-Kondo A; Nagao M
Transplant Cell Ther; 2022 Jul; 28(7):365.e1-365.e7. PubMed ID: 35460928
[TBL] [Abstract][Full Text] [Related]
6. Unstimulated apheresis for chimeric antigen receptor manufacturing in pediatric/adolescent acute lymphoblastic leukemia patients.
Jarisch A; Rettinger E; Sörensen J; Klingebiel T; Schäfer R; Seifried E; Bader P; Bonig H
J Clin Apher; 2020 Sep; 35(5):398-405. PubMed ID: 32750197
[TBL] [Abstract][Full Text] [Related]
7. Apheresis for chimeric antigen receptor T-cell production in adult lymphoma patients.
Harrer DC; Heidenreich M; Fante MA; Müller V; Haehnel V; Offner R; Burkhardt R; Herr W; Edinger M; Wolff D; Thomas S; Brosig A
Transfusion; 2022 Aug; 62(8):1602-1611. PubMed ID: 35851959
[TBL] [Abstract][Full Text] [Related]
8. Optimizing autologous nonmobilized mononuclear cell collections for cellular therapy in pediatric patients with high-risk leukemia.
Even-Or E; Di Mola M; Ali M; Courtney S; McDougall E; Alexander S; Schechter T; Whitlock JA; Licht C; Krueger J
Transfusion; 2017 Jun; 57(6):1536-1542. PubMed ID: 28439898
[TBL] [Abstract][Full Text] [Related]
9. Autologous lymphapheresis for the production of chimeric antigen receptor T cells.
Allen ES; Stroncek DF; Ren J; Eder AF; West KA; Fry TJ; Lee DW; Mackall CL; Conry-Cantilena C
Transfusion; 2017 May; 57(5):1133-1141. PubMed ID: 28236305
[TBL] [Abstract][Full Text] [Related]
10. [Clinical experience of leukapheresis for CD19 CAR-T cell therapy].
Jo T; Yoshihara S; Arai Y; Ikemoto J; Onomoto H; Sugiyama H; Yoshihara K; Matsui K; Niwa N; Nakagawa Y; Kitawaki T; Kanda J; Takaori-Kondo A; Nagao M
Rinsho Ketsueki; 2021; 62(3):163-169. PubMed ID: 33828008
[TBL] [Abstract][Full Text] [Related]
11. Optia® continuous mononuclear collection (CMNC) system is a safe and efficient system for hematopoietic progenitor cells-apheresis (HPC-a) collection and yields a lower product hematocrit (HCT%) than the COBE® spectra system: A retrospective study.
Pandey S; Cottler-Fox M
J Clin Apher; 2018 Aug; 33(4):505-513. PubMed ID: 29603795
[TBL] [Abstract][Full Text] [Related]
12. Incidence and Risk Factors Associated with Infection after Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory B-cell Malignancies.
Zhu F; Wei G; Liu Y; Zhou H; Wu W; Yang L; Huang H; Hu Y
Cell Transplant; 2021; 30():9636897211025503. PubMed ID: 34144648
[TBL] [Abstract][Full Text] [Related]
13. Low-cost generation of Good Manufacturing Practice-grade CD19-specific chimeric antigen receptor-expressing T cells using piggyBac gene transfer and patient-derived materials.
Ramanayake S; Bilmon I; Bishop D; Dubosq MC; Blyth E; Clancy L; Gottlieb D; Micklethwaite K
Cytotherapy; 2015 Sep; 17(9):1251-67. PubMed ID: 26212611
[TBL] [Abstract][Full Text] [Related]
14. CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.
Singh N; Frey NV; Grupp SA; Maude SL
Curr Treat Options Oncol; 2016 Jun; 17(6):28. PubMed ID: 27098534
[TBL] [Abstract][Full Text] [Related]
15. Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis.
Zhang T; Cao L; Xie J; Shi N; Zhang Z; Luo Z; Yue D; Zhang Z; Wang L; Han W; Xu Z; Chen H; Zhang Y
Oncotarget; 2015 Oct; 6(32):33961-71. PubMed ID: 26376680
[TBL] [Abstract][Full Text] [Related]
16. Lack of defined apheresis collection criteria in publicly available CAR-T cell clinical trial descriptions: Comprehensive review of over 600 studies.
Thibodeaux SR; Aqui NA; Park YA; Schneiderman J; Su LL; Winters JL; Zubair AC; Schwartz J; Liu HD;
J Clin Apher; 2022 Jun; 37(3):223-236. PubMed ID: 35085413
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of lymphoblastic leukemia with CD19-specific modified chimeric antigen receptor T cells].
Li HH; Zhu P; Wu XQ; Liu YF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Dec; 22(6):1753-6. PubMed ID: 25543510
[TBL] [Abstract][Full Text] [Related]
18. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.
Kebriaei P; Singh H; Huls MH; Figliola MJ; Bassett R; Olivares S; Jena B; Dawson MJ; Kumaresan PR; Su S; Maiti S; Dai J; Moriarity B; Forget MA; Senyukov V; Orozco A; Liu T; McCarty J; Jackson RN; Moyes JS; Rondon G; Qazilbash M; Ciurea S; Alousi A; Nieto Y; Rezvani K; Marin D; Popat U; Hosing C; Shpall EJ; Kantarjian H; Keating M; Wierda W; Do KA; Largaespada DA; Lee DA; Hackett PB; Champlin RE; Cooper LJ
J Clin Invest; 2016 Sep; 126(9):3363-76. PubMed ID: 27482888
[TBL] [Abstract][Full Text] [Related]
19. Advantages of high cell concentration prior to cryopreservation of initial leukapheresis in CAR-T cell therapy.
Carbonell D; Monsalvo S; Catalá E; Pérez-Corral A; Villegas C; Falero C; Ruano G; Martinez M; Kwon M; Muñoz-Martínez C; Díez-Martín JL; Gayoso J; Anguita J
Blood Transfus; 2024 May; 22(3):239-245. PubMed ID: 38063787
[TBL] [Abstract][Full Text] [Related]
20. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.
Schubert ML; Schmitt A; Sellner L; Neuber B; Kunz J; Wuchter P; Kunz A; Gern U; Michels B; Hofmann S; Hückelhoven-Krauss A; Kulozik A; Ho AD; Müller-Tidow C; Dreger P; Schmitt M
BMJ Open; 2019 May; 9(5):e026644. PubMed ID: 31110096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
